Safety of Glucocorticoid Therapy in Early-Stage Rheumatoid Arthritis

Controversy Surrounding Glucocorticoid Tolerability

Glucocorticoid therapy has been a topic of debate regarding its safety for patients with rheumatoid arthritis (RA). While these medications can be effective, long-term use is often associated with adverse effects, including cardiovascular disease (CVD), infections, diabetes, weight gain, osteoporosis, and fractures.

Research Overview

A study conducted by French researchers aimed to analyze the tolerability of glucocorticoids and their impact on mortality, CVD, severe infections, and fractures in a cohort of patients with recent-onset RA. This research was part of the Etude et Suivi des POlyarthrites Indifférenciées Récentes (ESPOIR) Study, which followed 602 patients who met the criteria for RA and were prescribed glucocorticoids.

Study Design and Patient Selection

Patients with pre-existing conditions such as CVD, severe infections, or fractures were excluded from the study. The remaining participants were divided into two groups: those who received glucocorticoids and those who did not. Over a follow-up period of seven years, researchers evaluated all-cause mortality, CVD incidents (including myocardial ischemia, cerebrovascular accidents, and heart failure), severe infections, and fractures as primary outcomes.

Factors Considered in the Analysis

The study also accounted for various covariates, including age, gender, body mass index (BMI), diabetes, hypertension, smoking status, hypercholesterolemia, and the use of non-steroidal anti-inflammatory drugs (NSAIDs). Additionally, a variable termed “cardiovascular risk” was created, indicating the presence of at least one cardiovascular risk factor among hypertension, hypercholesterolemia, a BMI over 30 kg/m², diabetes, and smoking.

Key Findings

The researchers found no significant differences in outcomes between the two groups. Notably, most patients in the glucocorticoid group were treated with low-dose glucocorticoids, suggesting a favorable tolerability profile in early-stage rheumatoid arthritis.